STM Journals Peer-reviewed research from Consortium e-Learning Network

Research and Reviews: A Journal of Pharmacology Review Article

Visualization of genomic sequence in BRCA1 and BRCA2

  1. Mandeep Kaur Maa Saraswati Institute of Pharmaceutical Sciences, Sitto Road, Abohar,
  2. Amit Chawla Maa Saraswati Institute of Pharmaceutical Sciences, Sitto Road, Abohar,
  3. Bharti Maa Saraswati Institute of Pharmaceutical Sciences, Sitto Road, Abohar
  4. Payal Rani Seth GL Bihani SD college of Tech. Edu. Sriganganagar
  5. Mangilal Maa Saraswati Institute of Pharmaceutical Sciences, Sitto Road, Abohar
  6. Vikramjit Singh Maa Saraswati Institute of Pharmaceutical Sciences, Sitto Road, Abohar
  7. Sachin Poonia Maa Saraswati Institute of Pharmaceutical Sciences, Sitto Road, Abohar
  8. Mohit Maa Saraswati Institute of Pharmaceutical Sciences, Sitto Road, Abohar
  9. Lovepreet Maa Saraswati Institute of Pharmaceutical Sciences, Sitto Road, Abohar

Abstract

Heredity is the main reason of breast cancer in women and mutation or genetic variations also another reason for the spread of breast cancer. Heredity and genetic variations are responsible 5%-10%, 30%-50% respectively. There are 90% chances of developing neoplasm by the mutations. The effect of BRCA1 and BRCA2 may leads to the variations in DNA therefore it should be in limited amounts so that there will be minimum changes in DNA. The BRCA1 and BRCA2 helps to repair or heal the DNA sequences but it grows rapidly and causes cancer. BRCA1 and BRCA2 can carry out for the patients who have the past occurrence (family history) of the carcinoma. The past history is done by the clinical evidence or diagnosis of the particular patient.For the diagnosis, we can use the various methods blood test, mammogram, breast ultrasound, biopsy etc.The ayurvedic and allopathic treatment is useful for the cure of various kinds of cancers, the ayurvedic medicines such as herbal drugs are helpful because they have the anti-cancer properties as well as the allopathic treatment is also required because the tumour is suppress by these and the examples of pharmacological treatment like alkylating agents, plant producers, etc. BRCA1 and BRCA2 are cancer suppressor genes, the sequence of these coding regions shows no similarity to the proteins with each other. If one copy in the gene is mutated, the result becomes hereditary and transfer breast and ovarian cancer fronm one generation to other generation.

Keywords

References (28)

  1. Agarwal G, Ramakant P. Breast Cancer Care in India: The Current Scenario and the Challenges for the Future. Breast Care. 2008;3(1):21-27. doi:10.1159/000115288
  2. Antoniou A, Pharoah PD, Narod SA, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72(5):1117–30.
  3. Chang J, Elledge RM. Clinical management of women with genomic BRCA1 and BRCA2 mutations*. Breast Cancer Research and Treatment. 2001;69(2):101-113. doi:10.1023/a:1012203917104
  4. Claus EB, Schildkraut J, Iversen ES, Berry D, Parmigiani G. Effect of BRCA1 and BRCA2 on the Association Between Breast Cancer Risk and Family History. JNCI Journal of the National Cancer Institute. 1998;90(23):1824-1829. doi:10.1093/jnci/90.23.1824
  5. Eeles RA. Future possibilities in the prevention of breast cancer: Intervention strategies in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research. 2000;2(4). doi:10.1186/bcr70
  6. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The American Journal of Human Genetics. 1998 Mar 1;62(3):676-89.
  7. Fejerman L, Romieu I, John EM, Lazcano-Ponce E, Huntsman S, Beckman KB, et al. European Ancestry Is Positively Associated with Breast Cancer Risk in Mexican Women. Cancer Epidemiology, Biomarkers & Prevention. 2010;19(4):1074-1082. doi:10.1158/1055-9965.epi-09-1193
  8. American Cancer Society. Survival rates for breast cancer. Last revised November 8, 2021.https://www.cancer.org/content/dam/CRC/PDF/Public/8580.00.pdf
  9. Sung JS. High-quality breast ultrasonography. Radiologic Clinics. 2014 May 1;52(3):519-26 https://www.radiologic.theclinics.com/article/S0033-8389(14)00029-3/abstract .
  10. Jernstrom H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, Daly M, Olopade OI, Foulkes WD, Warner E, Brunet JS, Narod SA. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 1999; 354:1846–50 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(99)04336-6/fulltext
  11. Jaradat NA, Shawahna R, Eid AM, Al-Ramahi R, Asma MK, Zaid AN. Herbal remedies use by breast cancer patients in the West Bank of Palestine. Journal of Ethnopharmacology. 2016;178:1-8. doi:10.1016/j.jep.2015.11.050
  12. Komen S. Resources AMERICAN CANCER SOCIETY Know what is normal for you. Available from: https://www.komen.org/wp-content/uploads/Screening-and-Early-Detection-Tri-Fold-9-15-FINAL.pdf
  13. MacMahon B. Epidemiology and the causes of breast cancer. International Journal of Cancer. 2006;118(10):2373-2378. doi:10.1002/ijc.21404
  14. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nature Reviews Cancer. 2004;4(9):665-676. doi:10.1038/nrc1431
  15. Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J, et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genetics. 1996;13(1):126-128. doi:10.1038/ng0596-126
  16. O'Donovan PJ, Livingston DM. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis. 2010;31(6):961-967. doi:10.1093/carcin/bgq069
  17. Perrin-Vidoz L. The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Human Molecular Genetics. 2002;11(23):2805-2814. doi:10.1093/hmg/11.23.2805
  18. Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG. ‘Hormonal’ risk factors, ‘breast tissue age’ and the age-incidence of breast cancer. Nature. 1983;303(5920):767-770. doi:10.1038/303767a0
  19. Rahman N, Stratton MR. THE GENETICS OF BREAST CANCER SUSCEPTIBILITY. Annual Review of Genetics. 1998;32(1):95-121. doi:10.1146/annurev.genet.32.1.95
  20. Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K. 2010. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol28: 893–901.
  21. SIMINOFF L. A. and FETTING H. J. L. “The Johns Hopkins Oncology Center, Baltimore, MD 21218, U.S.A.” Printed in Great Britain, Sot. Sci. Med. Vol. 32, No. 7, pp. 813-818, 1991
  22. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nature Genetics. 1995;11(2):198-200. doi:10.1038/ng1095-198
  23. Clemons AN. Susan G. Komen for the cure and the planned parenthood federation of America: A framework for non-profits beginning and ending a relationship with another organization (Doctoral dissertation) http://hdl.handle.net/2152/32180 .
  24. Tesoriero A, Andersen C, Southey M, et al. De novoBRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation. Am J Hum Genet1999; 65: 567–9.
  25. Trainer AH, Lewis CR, Tucker K, Meiser B, Friedlander M, Ward RL. 2010. The role of BRCA mutation testing in determining breast cancer therapy. Nat Rev Clin Oncol7:708–717.
  26. Tsongalis GJ, Linfert DR, Johnson RC, et al. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient. Arch Pathol Lab Med1998; 122: 548–50.
  27. Walode G. sanjay, s. chandan edition 3rd “a text book of medicinal chemistry-II” published by niraliprakashan 2.5 to 2.16.
  28. Breast cancer - Diagnosis and treatment - Mayo Clinic [Internet]. Mayoclinic.org. ; 2024 [cited 2025 Feb 1]. Available from: https://www.mayoclinic.org/diseases-conditions/breast-cancer/diagnosis-treatment/drc-20352475 ‌
Support